6 completed, 2 unknown, 1 terminated. 4 Phase 1, 3 Phase 2, 2 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Unknown 1 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 4 | 1 | Terminated 1 |
Follow etesevimab: new trials by email Literature Review of etesevimab trials Research Report on etesevimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19 JS026/placebo, JS016/placebo - COVID-19 | Phase 1 | Completed | Shanghai Junshi Bioscience Co., Ltd. | 48 | 2021-12-16 | 2023-08-01 |
| UPMC OPTIMISE-C19 Trial, a COVID-19 Study Lilly Bamlanivimab, Regeneron Casirivimab + Imdevimab, Lilly Bamlanivimab + Etesevimab - Covid19 | Phase 4 | Terminated | Erin McCreary | 4571 | 2021-03-10 | 2023-06-15 |
| Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19) JS016 - COVID-19, SARS-CoV-2 | Phase 2 | Unknown | Peking Union Medical College Hospital | 200 | 2021-01-20 | 2021-10-21 |
| A Study of LY3832479 (LY-CoV016) in Healthy Participants 1 LY3832479, Placebo - Healthy | Phase 1 | Completed | Eli Lilly and Company | 18 | 2020-11-02 | 2021-12-06 |
| A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness Bamlanivimab, Etesevimab, Placebo - COVID-19 | Phase 2 | Completed | Eli Lilly and Company | 1755 | 2020-10-29 | 2022-07-01 |
| A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff Bamlanivimab, Placebo, Etesevimab - COVID-19, SARS-CoV2 | Phase 3 | Completed | Eli Lilly and Company | 1180 | 2020-08-02 | 2022-02-04 |
| A Study of LY3832479 (LY-CoV016) in Healthy Participants LY3832479, Placebo - Healthy | Phase 1 | Completed | Eli Lilly and Company | 26 | 2020-06-19 | 2021-12-06 |
| A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness LY3819253, LY3832479, LY3853113 - COVID-19 | Phase 2 / Phase 3 | Completed | Eli Lilly and Company | 3307 | 2020-06-17 | 2024-04-11 |
| Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects JS016 (anti-SARS-CoV-2 monoclonal antibody) - COVID-19; and High Infection Risk of SARS-CoV-2 | Phase 1 | Unknown | Shanghai Junshi Bioscience Co., Ltd. | 40 | 2020-06-05 | 2020-06-22 |
COVID-19 (7)
Eli Lilly and Company (5) · Shanghai Junshi Bioscience Co., Ltd. (2) · Erin McCreary (1) · Peking Union Medical College Hospital (1)
United States (6) · China (3) · Argentina (1) · Puerto Rico (1)
Bin DU, Prof. (1) · David T Huang, MD, MPH (1) · Erin McCreary, PharmD (1)
PMID 34473343, PMID 35713300, PMID 34374951, PMID 33113295, PMID 33215063, PMID 33475701, PMID 33972256, PMID 34034784, PMID 34081073, PMID 34260849, PMID 34346827, PMID 34718468, PMID 35191746, PMID 35493124, PMID 35697146, PMID 35834252, PMID 37329415, PMID 38291279, PMID 39230829